Director/PDMR Shareholding

RNS Number : 6473V

Advanced Medical Solutions Grp PLC

19 April 2016

 

19 April 2016

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Directors' Shareholdings

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP') on 18 April 2016.  The vesting period of these options is subject to certain performance criteria over a three year period.

Director	Options prior to grant	Options granted	Resultant holding
Chris Meredith Chief Executive Officer	938,439	143,553	1,081,992
Mary Tavener Chief Financial Officer	568,155	111,050	679,205

Advanced Medical Solutions Group plc also announces that on 18 April 2016, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the '2014 DAB').

This award is in respect of the part of their bonus that the Directors are compulsorily required to defer for the 2015 financial year. These options vest at the end of three years.

Director	Options prior to grant	Options granted	Resultant holding
Chris Meredith Chief Executive Officer	49,580	32,638	82,218
Mary Tavener Chief Financial Officer	36,538	21,332	57,870

-     Ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Gary Clarence / Daniel Adams / Patrick Robb

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 510 employees.  For more information please see www.admedsol.com.

 

END

 

 

DSHGCGDSRUBBGLC